NCT07037862招募中1 期
A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping With an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-44, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-44 (ELEVATE-44)
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 24
- 试验地点
- 23
- 主要终点
- Number of participants with Treatment Emergent Adverse Events (TEAEs) according to study protocol (Part A and Open Label (OL) Period)
研究概览
简要总结
This is a study of the investigational medicine ENTR-601-44 in participants who have Duchenne muscular dystrophy (DMD), a rare genetic condition.
The researchers want to: Test how safe ENTR-601-44 is, learn about any side effects, and look at the potential positive effects of ENTR-601-44, compared to placebo. Placebo looks like the investigational medicine but does not contain any active ingredient. In this summary ENTR-601-44 and placebo are both called study treatments.
The study has 2 parts:
-
Part A
-
A Double-Blind Period, to evaluate if ENTR-601-44 is safe and to determine the best dose of ENTR-601-44 for Part B.
-
Following the Double-Blind period, participants will roll into an open-label treatment period during which the safety and efficacy of extended dosing will be evaluated.
-
Part B
-
To further evaluate the effect and safety of ENTR-601-44 at the dose determined in Part A.
Participants will:
- Receive study treatment in the form of multiple intravenous (IV) infusions (slow injection) into a vein over the course of several weeks in Part A and in Part B
- Visit the clinic regularly for checkups and tests such as: blood and urine tests, physical examinations, questionnaires, and exercise tests. Participants will have a muscle biopsy at the beginning of their participation and after their last dose to allow researchers to compare whether there have been changes in the muscle as a result of the study drug.
Participants are allowed to continue receiving their standard of care therapy for DMD during the study, as long as their health remains stable.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 4 Years 至 20 Years（Child, Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Principal inclusion criteria
- •Genetic diagnosis of Duchenne muscular dystrophy (DMD) and confirmed pathologic variant in the dystrophin gene amenable to exon 44 skipping as reviewed by a central genetic counselor.
- •Assigned male at birth with clinical signs compatible with Duchenne muscular dystrophy as determined by the investigator.
- •Part A: 4-20 years of age, inclusive.
- •Ambulatory Status Part A: ambulatory with a Performance of the Upper Limb v2.0 (PUL 2.0) Entry as per protocol at Screening
- •Adequate muscle for obtaining tissue biopsy as assessed by the investigator.
- •Other protocol-defined criteria apply.
排除标准
- •Any significant concomitant medical condition that might interfere with the ability to comply with protocol requirements.
- •Has an acute illness within 4 weeks prior to the first dose of study drug which may interfere with study measurements or jeopardize participant's safety.
- •Use of the following medications:
- •Prior treatment with any exon skipping therapy at any time
- •Prior treatment with any gene therapy at any time
- •Use of anti-coagulants, anti-thrombotics, or anti-platelet agents
- •Use of an immunosuppressants (other than oral corticosteroids for DMD conditions)
- •Has taken or is currently taking a histone deacetylase (HDAC) inhibitor, including (but not limited to) givinostat
- •Laboratory abnormalities.
- •Daytime ventilator dependence or any use of invasive mechanical ventilation via tracheostomy.
- •Has an abnormal electrocardiogram (ECG) reading assessed as clinically significant by the investigator, and/or a QT interval with Fridericia correction method (QTcF) >450 msec at Screening or prior to the first dose of study drug on Day
- •Received any experimental or investigational drug, etc. within 3 months prior to first dose or within 5 half-lives (whichever is longer).
- •Other protocol-defined criteria apply.
研究组 & 干预措施
Placebo
Placebo Comparator
intravenous infusion every 6 weeks
干预措施: ENTR-601-44 - matching placebo (Drug)
ENTR-601-44
Experimental
intravenous infusion every 6 weeks
干预措施: ENTR-601-44 (Drug)
结局指标
主要结局
Number of participants with Treatment Emergent Adverse Events (TEAEs) according to study protocol (Part A and Open Label (OL) Period)
时间窗: From baseline through End of Study (up to 62 weeks).
Safety will be assessed by monitoring adverse events, physical examination, vital signs and clinical laboratory tests.
次要结局
- Change from baseline to End of OL Period in Performance of the Upper Limb v2.0 (PUL 2.0) (Part A and OL Period)(Baseline, End of Study (up to 62 weeks))
- Change from baseline to End of OL Period in 95th centile Stride Velocity (SV95C) (Part A and OL Period)(Baseline, End of Study (up to 62 weeks))
- Change from baseline to End of OL Period in North Star Ambulatory Assessment (NSAA) (Part A and OL Period)(Baseline, End of Study (up to 62 weeks))
- Change from baseline to End of Part A in dystrophin by Western blot from muscle biopsy (Part A)(Baseline, End of Part A (up to 25 weeks))
- Change from baseline to End of Part A in dystrophin expression and localization from muscle biopsy (Part A)(Baseline, End of Part A (up to 25 weeks))
- Change from baseline to End of OL Period in Timed Rise from Floor (Part A and OL Period)(Baseline, End of Study (up to 62 weeks))
- Change from baseline to End of OL Period in Timed 4-Stair Climb (4SC) (Part A and OL Period)(Baseline, End of Study (up to 62 weeks).)
- Plasma, muscle, and urine concentration of ENTR-601-44 and its final metabolite (Part A and Open Label (OL) Period)(From Baseline through End of Study (up to 62 weeks).)
- Change from baseline to End of Part A in dystrophin by Western blot from muscle biopsy (Part A)(Baseline, End of Part A (up to 25 weeks))
- Change from baseline to End of Part A in dystrophin expression and localization from muscle biopsy (Part A)(Baseline, End of Part A (up to 25 weeks))
- Percent change from baseline to End of Part A in exon 44 skipping measured in muscle biopsy at End of Study (Part A)(Baseline, End of Part A (up to 25 weeks))
- Anti-drug antibody (ADA) and anti-dystrophin antibody in serum (Part A and OL Period)(From baseline through End of Study (up to 62 weeks).)
- Change from baseline to End of OL Period in 10-Meter Walk/Run (10MWR) (Part A and OL Period)(Baseline, End of Study (up to 62 weeks))
- Change from baseline to End of OL Period in Timed Rise from Floor (Part A and OL Period)(Baseline, End of Study (up to 62 weeks))
- Change from baseline to End of OL Period in Timed 4-Stair Climb (4SC) (Part A and OL Period)(Baseline, End of Study (up to 62 weeks).)
- Change from baseline to End of OL Period in 95th centile Stride Velocity (SV95C) (Part A and OL Period)(Baseline, End of Study (up to 62 weeks))
- Change from baseline to End of OL Period in North Star Ambulatory Assessment (NSAA) (Part A and OL Period)(Baseline, End of Study (up to 62 weeks))
- Change from baseline to End of OL Period in Performance of the Upper Limb v2.0 (PUL 2.0) (Part A and OL Period)(Baseline, End of Study (up to 62 weeks))
研究者
研究点 (23)
Loading locations...
相似试验
已完成
1 期
Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular DystrophyMuscular Dystrophy, DuchenneNCT00243789Cooperative International Neuromuscular Research Group64
进行中（未招募）
不适用
Duchenne muscular dystrophy: a clinical trial to find the optimum steroid regimen.Duchenne muscular dystrophy boys between 4 and 8 years of age, able to rise from the floor without support, not previously treated with steroids.MedDRA version: 14.1Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2010-023744-33-ITAZIENDA OSPEDALIERA DI PADOVA300
进行中（未招募）
不适用
Trial to find best steroid treatment for Duchenne muscular dystrophyDuchenne muscular dystrophy (DMD)MedDRA version: 14.1Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2010-023744-33-GBniversity of Rochester300
已完成
3 期
Finding the Optimum Regimen for Duchenne Muscular DystrophyDuchenne Muscular DystrophyNCT01603407University of Rochester196
已完成
1 期
Safety Study of BLS-M22 in Healthy VolunteersMuscular Dystrophy, DuchenneNCT03789734BioLeaders Corporation37